Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston's Welch Foundation has awarded more than 80 grants to support chemical research and careers in Texas for 2025. Photo via Getty Images

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

From Your Site Articles
In all, the Welch Foundation on June 4 announced more than $40.5 million in academic research grants, equipment grants, and fellowships. Photo via Getty Images

Texas organization grants over $40M to chemistry research in Houston and beyond

fresh funding

Two local professors are among the newly announced recipients of funding from the Houston-based Welch Foundation, which finances chemical research projects.

The two professors are:

  • Jacinta Conrad, the Frank M. Tiller Professor in the Chemical and Biomolecular Engineering Department at the University of Houston. Conrad will use her grant to investigate glass transition, a temperature change that affects polymers. She describes glass transition as one of the “most intriguing open problems in physical chemistry.”
  • James Shee, assistant professor in the Chemistry Department at Rice University. Shee will put his grant toward advancing theoretical chemistry.

Every year, the foundation provides annual grants totaling at least $100,000 to support chemistry research being carried out by full-time faculty members at colleges, universities, and other educational institutions in Texas.

In all, the Welch Foundation on June 4 announced more than $40.5 million in academic research grants, equipment grants, and fellowships.

Part of the announced funding will go toward the foundation’s new Postdoctoral Fellows Grant Program. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. A total of $900,000 in postdoctoral fellowships were funded at Rice University, Texas A&M University, and the University of Texas at Austin.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs, and other chemistry-related ventures.

“Ongoing basic chemical research is critically important for helping to solve current and future problems,” said Adam Kuspa, President of the Welch Foundation. “We strongly believe the foundation’s continued support of the research grant program, combined with … new programs, will yield even more exciting developments as we work to advance chemistry and improve our lives.”

The Welch Foundation, a Houston-based nonprofit, has doled out fresh funding to research organizations, with over a third being deployed to Houston-area institutions. Photo via Getty Images

Houston organization announces nearly $28M in Texas research grant funding

money moves

Five schools in the Houston area have landed $10.8 million in research grants from the Houston-based Welch Foundation.

The 36 grants were awarded to Rice University, Texas A&M University, the University of Houston, the Baylor College of Medicine, and the University of Texas Medical Branch in Galveston.

In all, the foundation announced nearly $28 million in Texas research grants for 2023. All of the money — in the form of 91 grants for 15 Texas colleges and universities — goes toward chemical research. This year’s total for grant funding matches last year’s total.

“The Welch Foundation continues to emphasize the creative pursuit of basic chemical research,” Adam Kuspa, the foundation’s president and a former dean at the Baylor College of Medicine, says in a news release. “Our funding allows investigators throughout the state to follow their curiosity and explore the foundations chemical processes.”

Since its establishment in 1954, the Welch Foundation has contributed about $1.1 billion to the advancement of chemistry in Texas.

One of this year’s local grant recipients is Haotian Wang, assistant professor in Rice’s chemical and biomolecular department. The professor’s grant-funded research will focus on the conversion of carbon dioxide into useful chemicals, such as ethanol.

Last year, Rice reported that Wang’s lab in the George R. Brown School of Engineering had replaced rare, expensive iridium with ruthenium, a more abundant precious metal, as the positive-electrode catalyst in a reactor that splits water into hydrogen and oxygen.

The lab’s addition of nickel to ruthenium dioxide resulted in production of hydrogen from water electrolysis for thousands of hours.

“There’s huge industry interest in clean hydrogen,” Wang says. “It’s an important energy carrier and also important for chemical fabrication, but its current production contributes a significant portion of carbon emissions in the chemical manufacturing sector globally.”

“We want to produce it in a more sustainable way,” he adds, “and water-splitting using clean electricity is widely recognized as the most promising option.”

Houston-based Welch Foundation has awarded almost $28 million in chemical research grants throughout Texas this year. Photo via Getty Images

Houston research organization doles out $28M in grants to innovators across Texas

funding for the future

Chemical researchers at seven institutions in the Houston area are receiving nearly $12.9 million grants from the Houston-based Welch Foundation.

In the Houston area, 43 grants are going to seven institutions:

  • Baylor College of Medicine
  • Rice University
  • Texas A&M University
  • Texas A&M University Health Science Center
  • University of Houston
  • University of Texas Health Science Center at Houston
  • University of Texas Medical Branch in Galveston

The Welch Foundation is awarding almost $28 million in chemical research grants throughout Texas this year. The money will be allocated over a three-year period.

“Today, chemical research is more important than ever for improving the human condition and for meeting the global challenges that threaten our collective future,” says Adam Kuspa, president of the Welch Foundation. “Basic research in chemistry and related fields provides the foundation for groundbreaking scientific discoveries that can help solve current problems and sustain progress.”

Two of the 2022 grant recipients cited by the foundation are:

  • Josephine Chu Ferreon, assistant professor of pharmacology and chemical Biology at the Baylor College of Medicine. She plans to use her Welch grant to conduct research on intrinsically disordered proteins (IDPs) and their potential applications in biotech and nanomedicine. IDPs, known as “dancing proteins,” do not form uniquely defined 3D structures. Because of the structural flexibility, IDPs can pair with ordered proteins to perform functions that structured proteins can’t do on their own.
  • David Powers, assistant professor of chemistry at Texas A&M. He leads a research group focused on the relationship between organic and inorganic chemistry. Members of the group are trying to develop new methods for the sustainable synthesis of functional molecules.

Since its establishment in 1954, the Welch Foundation has contributed more than $1.1 billion to the advancement of chemistry in Texas. Last year, the organization granted $23 million in funds.

The Welch Foundation has announced millions in Texas research funding. Photo via Getty Images

Houston-based research grant program doles out $23M to Texas scientists

funds for the future

One of the nation's largest private funders for health care research has announced $23 million in fresh funds — and about a third of that is going into the hands of Houstonians.

The Welch Foundation, based in Houston, announced its 2021 research grant funding last week. Over the next three years, the funds will be be distributed in $7,520,000 payouts annually across the state of Texas. Since its founding in 1954, the foundation has doled out almost $1.1 billion to the advancement of chemistry.

"Ongoing basic chemical research is critical and provides the building blocks to help solve current and future problems," says Adam Kuspa, president of The Welch Foundation, in a news release. "Funding from The Welch Foundation is a valuable resource to Texas institutions. It helps set our state's researchers apart from others and we look forward to seeing what invaluable scientific contributions come from this year's grant recipients."

The universities in the Houston area that received a cut of this chunk of funding include Rice University, Texas A&M University, University of Houston, and Baylor College of Medicine for a total of $8,400,000 across 35 grants.

One of the Houston-area researchers who received funding is Leila Romero, assistant professor and CPRIT Scholar in Cancer Research at Baylor University's Department of Chemistry and Biochemistry. Romero and her team is exploring modes of asymmetric catalysis and to study how these new processes work. According to the release, the funding will also support the training of young graduate students at the institution who are on track to become future innovators in chemical synthesis.

Other Texas institutions in other major cities also received funding:

  • The Dallas/Fort Worth area received funding for 42 grants, totaling $10,080,000. The University of Texas Southwestern Medical Center, The University of Texas at Dallas, University of North Texas, Baylor University, Southern Methodist University, and Texas Christian University were the recipient institutions.
  • In Austin, the University of Texas Received funding for 11 grants, totaling $2,640,000.
  • The University of Texas at San Antonio and Trinity University received the three grants — totaling $720,000 — that went to the San Antonio area.
  • In West Texas, The University of Texas at El Paso received funding for 1 grant, totaling $240,000.
  • Texas Tech University received funding for two grants, totaling $480,000

Last year, the Welch Foundation announced a $100 million gift to Rice University to establish The Welch Institute. The institute will foster the study of matter, the design and discovery of new materials, and nanotechnology, and it will be led by an independent board of directors and scientific advisory board.

Kuspa, who's led the foundation since September 2019, joined the Houston Innovators Podcast last December to discuss the new institute and the importance of supporting researchers in Texas.


This week's innovators to know roundup includes Heath Butler and Samantha Lewis of Mercury Fund and Adam Kuspa of the Welch Foundation. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: In this week's Monday roundup of Houston innovators, I'm introducing you to three innovators across the city — each in their own ways financially support the region's top innovators.


Heath Butler and Samantha Lewis of Mercury Fund

Heath Butler has been promoted to managing director of Mercury Fund, and Samantha Lewis joins the firm as principal. Photos courtesy

Houston-based Mercury Fund, which focuses on early-stage startups located in central United States, announced the promotion of Heath Butler to managing director from network partner. Additionally, Samantha Lewis — formerly investment director at Houston-based Goose Capital — is joining the fund as principal.

"Over the past few years, we've continued to build our investment team with top talent from our ecosystem," says Blair Garrou, co-founder and managing director of Mercury, in a news release.

"The promotion of Heath and the addition of Samantha will further Mercury's early-stage venture leadership in Middle America, and is illustrative of Mercury's deep commitment to diversity as a core value driver," continues Garrou. Click here to read more.

Adam Kuspa of The Welch Foundation

Adam Kuspa of The Welch Foundation joins the Houston Innovators Podcast to discuss the COVID-19 vaccine, materials science, and more. Photo courtesy of The Welch Foundation

It's been an interesting year for Adam Kuspa and the Welch Foundation as — just like any other organization — the pandemic has caused various disruptions for Kuspa and his team. At the same time, COVID-19 has forced an unprecedented public-private response from the medical community, the government, and more.

"I'm very proud of the scientific enterprise in this country and around the world — they way it's been supported, developed, and maintained over the years — to allow for something like this be even contemplated," Kuspa says on this week's episode of the Houston Innovators Podcast.

Over the last 40 to 50 years, researchers in the fields immunology, vaccine research, protein biochemistry, and more, have seen increased support, Kuspa says, and that's what made a difference in the pandemic and allowed for a vaccine to emerge so quickly. Click here to read more and to listen to the episode.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

4 Houston health tech startups advancing medical innovation

meet the finalists

Houston has been driving medical innovation for decades. And thanks to leading hospitals, cutting-edge research and breakthrough technologies, the region’s healthcare ecosystem continues to improve how patients are diagnosed, treated and cared for.

The Health Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup within the health and medical technology sectors.

Four forward-thinking businesses have been named finalists for the 2026 award. This year's finalists, selected by our esteemed panel of judges, range from a startup developing miniaturized medical technologies for space to a company using AI to help develop cancer treatment plans.

Read more about these businesses, their innovative founders, and how they're shaping the future of health care below.. The 2026 winners will be announced on InnovationMap.com in mid-November.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. The company raised an oversubscribed seed round for $2.4 million earlier this year and received Breakthrough Device Designation from the Food and Drug Administration in April.

InformAI Inc.

InformAI Inc. develops fit-to-purpose AI solutions for the clinical setting. Its RadOncAI product recently received FDA 510(k) clearance. The product uses AI to create a first-pass radiation therapy dose plan for complex head and neck cancers in an effort to eliminate bottlenecks in radiation planning and ultimately cancer treatment. The company has also developed AI products for sinus disease detection and 3D organ reconstruction.

CEO Jim Havelka founded the company in 2017. It is participating in the Mayo Clinic Accelerate Platform. It has raised about $4 million in seed funding and has received numerous non-dilutive grants from the National Science Foundation, the National Institutes of Health and the Cancer Prevention and Research Institute of Texas. The company shared in its application that it plans to launch a Series A fundraising round and submit an FDA 510K application for its organ reconstruction product, Voluquant, by the end of 2026.

Prana Surgical

Prana Surgical is developing a minimally invasive surgical platform for small, hard-to-reach lung nodules that may be cancerous. The company's Prana System cleared U.S. Food and Drug Administration (FDA) approval earlier this year.

Prana Surgical was originally founded as Prana Thoracic in 2022. It has participated in numerous accelerators, including the Texas Medical Center Innovation Accelerator in 2023 and the IGNITE Health accelerator in 2022. It raised $6 million in Series A funding rounds in 2023 and 2024 , with a Series B currently ongoing. The company said in its application that it is currently moving into the next stage of clinical validation and revenue generation in the U.S., in addition to preparing its manufacturing and commercial infrastructure for broader use.

Skybound MedTech

Skybound MedTech develops technologies that aim to address the health risks of long-duration spaceflight. Its compact, miniaturized medical technologies can deliver complex therapies without a physician.

CEO Matthew Kuhn, who previously founded Taurus Vascular, founded Skybound last year. The company emerged from stealth in January after raising a $1.25 million Series A round. It plans to advance its lead dual-use platform into critical preclinical validation in November, the company shared in its application. It is currently raising a $25 million Series A round and is pursuing federal research partnerships with DARPA and ARPA-H.

Generation Park lands new facility to scale xeno-organ production

Organ innovation

Maryland-based United Therapeutics Corp. has opened a new 77,448-square-foot facility to manufacture xeno-organs in Northeast Houston’s growing biotech hub, Generation Park.

The new Houston location is United Therapeutics’ third Designated Pathogen-Free (DPF) site, named for transplant pioneers Dr. Bartley P. Griffith and Dr. Robert A. Montgomery. The company says the new facility will enable it to scale commercial production of its xeno-organs once they receive regulatory approval.

An existing DPF facility in Virginia is supporting clinical trials for the xeno-organs, and a third site in Minnesota will also focus on commercialization with the Houston site, according to the company.

Xeno-organs are organs taken from a non-human animal source and transplanted, implanted or infused into a human recipient.

Currently, United Therapeutics is advancing clinical trials to support a Biologics License Application with the U.S. Food and Drug Administration for its investigational-stage xenotransplantation, UKidney, UThymoKidney and UHeart products. The products all involve working with the genes from humans and pigs.

In 2025, Chron.com reported the company was working to construct an estimated $96 million facility to breed genetically engineered animals. Head of investor relations at United Therapeutics Dewey Steadman told the Houston Business Journal in 2025 that the pigs’ DNA will be edited. In November 2024, a 53-year-old woman in Alabama received a transplanted kidney from UKidney that had 10 gene edits. She had the transplant removed in April 2025, after her body rejected it.

The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility requires a “strictly controlled, biosecure barrier environment, including air filtration, filtered water, filtered feed supplies, and state-of-the-art decontamination entryways,” according to the company. Being pathogen-free means it includes calibrated air and water conduits to support the transplantability of xenograft products and to prevent contamination. For energy considerations, the building also features solar arrays.

“With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them,” Martine Rothblatt, chairperson and CEO of United Therapeutics, said in a news release. “It is fitting that this facility is named for Dr. Griffith and Dr. Montgomery, whose first-in-human surgeries turned xenotransplantation from a theoretical possibility into a clinical reality.”

The facility, which wrapped construction in August, is located at 11848 Common Dock Dr. in Generation Park, which will house manufacturing sites for pharmaceutical heavyweights Bristol Myers Squibb and Eli Lilly. Last fall, Eli Lilly tapped Generation Park for its $6.5 billion manufacturing plant, and Bristol Myers Squibb made a $2.3 billion investment in August to bring its state-of-the-art site to the master-planned commercial district.

Elon Musk's SpaceX reports profit as AI and satellite businesses booms

Booming Business

SpaceX reported a bigger quarterly profit than expected on Tuesday, October 20, as its satellite communications and artificial intelligence businesses boomed.

The company, run by Elon Musk, posted a profit for the three months through September 2026 of $4.4 billion, or 35 cents per share, reversing a year-ago loss and easily topping Wall Street's expectations. Revenue soared to $14.6 billion, up 161%.

On a conference call with analysts, Musk suggested a merger with his electric car company Tesla might be in the works, something that has been rumored for months. He said both companies formed “special committees” of independent directors to discuss the issue, though he played down the chances of an imminent deal.

“Some people out there assume that a SpaceX and Tesla merger is a certainty,” he said. “I think that would be overstating it.”

The AI business became SpaceX's largest by revenue in the third quarter, although the Starlink satellite service remains the biggest profit generator.

“They beat across all metrics and the Starlink business looks to be accelerating,” said Dan Ives, an analyst at Yorkville Ives. “This is just what (Wall) Street wanted.”

The stock rose 7.5% in after-hours trading.

Musk also told analysts that for next month's launch of its Starship rocket, SpaceX will attempt to grab both the booster and ship with mechanical arms upon return to base, a key step toward demonstrating it can reuse the massive spacecraft.

“The only way that we can extend consciousness beyond Earth on a sustained basis is with a fully reusable orbital launch vehicle,” Musk said, calling the attempt, if successful, “a massive technology milestone.”

SpaceX hopes to get Starship on a regular launch pattern in preparation for NASA's upcoming lunar missions.

The company already has huge contracts with the federal government, and House Democrats have called for investigations into those contracts and Musk’s work with the Department of Government Efficiency. Musk has spent $276 million since July in support of Republican candidates.

In a filing for its initial public offering in June, SpaceX warned that a change in control of Congress could have a “material and adverse impact on our growth and competitive position.”

Musk recently drew criticism from politicians in Washington after speeds for a military version of SpaceX's satellite communications service were slowed for Ukraine following President Donald Trump's deal to get more diesel oil from Russia amid a push to end the war. The Wall Street Journal reported Tuesday that it was Musk who ordered the slowdown, impeding Ukraine’s use of drones along the front. SpaceX did not immediately respond to an Associated Press request for comment on the Journal story.

Both Trump and Musk have denied responsibility for the slowdown.

As midterm elections near, Musk on Monday promised to give one share of SpaceX to “every kid in America” next year, though he provided no details on how the distribution would be carried out. With communities nationwide protesting the construction of large data centers and concerns about AI safety, AI companies are trying to build goodwill. Anthropic pledged to commit 5% of its shares to a new “public benefit” fund.

SpaceX shares have been under pressure over concerns that the company was spending too much on major projects to compete with rivals such as Anthropic. The company said capital expenditures totaled $19.6 billion last quarter, nearly triple the figure from a year earlier, and it forecast spending would grow to $35 billion to $40 billion in the current quarter.

Shares of SpaceX closed Tuesday at $147.79, down from a peak near $201 after its IPO, which made Musk the world’s first trillionaire at the time. But the share prices for SpaceX and Tesla have since dropped, reducing his net worth to $925 billion, according to Forbes magazine.

Tesla reports third-quarter financial results Wednesday. Last week, Tesla unveiled a new Roadster sports car that in some versions may include thrusters allowing it to briefly fly using SpaceX technology — though experts say anything usable for drivers is a long shot.

View All Listings